✦ LIBER ✦

Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia A pediatric oncology group study

✍ Scribed by Barry L. Dowell; Michael J. Borowitz; James M. Boyett; D. Jeanette Pullen; William M. Crist; Fauzia F. Quddus; Edward C. Russell; John M. Falletta; Richard S. Metzgar

Publisher: John Wiley and Sons
Year: 1987
Tongue: English
Weight: 669 KB
Volume: 59
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19870615)59:12<2020::aid-cncr2820591209>3.0.co;2-i

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intensive alternating drug pairs for tre

Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A pediatric oncology group pilot study

✍ Stephen J. Lauer; Bruce M. Camitta; Brigid G. Leventhal; Donald H. Mahoney Jr.; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 682 KB

Impact of the timing of triple intrathec

Impact of the timing of triple intrathecal therapy on remission induction in childhood acute lymphoblastic leukemia: A pediatric oncology group study

✍ Hvizdala, Eva ;Berry, D. H. ;Chen, Timothy ;Dyment, Paul G. ;Kim, Tae H. ;Steube 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB

Five weekly doses of triple intrathecal (IT) chemotherapy (methotrexate, hydrocortisone, cytosine arabinoside) starting on day 1 of treatment were added to systemic induction therapy in a regimen (Arm 3) that was compared to three other regimens (Arms 1, 2, and 4) in which central nervous system (CN

A pilot study of intermediate-dose metho

A pilot study of intermediate-dose methotrexate and cytosine arabinoside, “Spread-out” or “Up-front,” in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia a pediatric oncology group study

✍ Robert A. Krance; Edward M. Newman; Donald Pinkel; Yaddanapudi Ravindranath; Mic 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

One hundred six children with newly diagnosed non-T-, non-B-cell acute lymphoblastic leukemia (ALL) were treated in a Pediatric Oncology Group (POG) pilot study in which six courses of intermediate-dose methotrexate (MTX) and cytosine arabinoside (Ara-C) (1 g/m2 each) were added to a "backbone" of s